001630.KS
Chong Kun Dang Holdings Corp.
KSC · Healthcare · Drug Manufacturers - Specialty & Generic · KR
KRW 38,900.00
−0.51%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 961.6B | 959.0B | 957.8B | 879.8B | 909.0B |
| Cost of Revenue | 561.8B | 543.1B | 513.2B | 495.9B | 509.8B |
| Gross Profit | 399.8B | 415.9B | 444.6B | 383.9B | 399.2B |
| Operating Expenses | |||||
| R&D Expense | 32.2B | 27.0B | 23.2B | 23.2B | 22.7B |
| SG&A Expense | 251.0B | 241.6B | 294.1B | 327.5B | 331.8B |
| General & Admin Expense | 10.0B | 14.3B | 31.4B | 28.3B | 25.7B |
| Selling & Marketing Expense | 216.8B | 227.3B | 262.7B | 230.2B | 306.1B |
| Other Expenses | 68.7B | 89.0B | 91.8B | 86.1B | 77.6B |
| Total Operating Expenses | 343.6B | 357.6B | 409.1B | 350.7B | 432.1B |
| Cost and Expenses | 905.5B | 900.7B | 922.3B | 846.6B | 941.8B |
| Operating Income (EBIT) | 56.2B | 58.3B | 35.5B | 33.1B | (32.9B) |
| Non-Operating | |||||
| Interest Income | 1.4B | 1.3B | 1.5B | 2.5B | 1.6B |
| Interest Expense | 21.3B | 20.7B | 20.6B | 19.6B | 10.8B |
| Net Interest Income | (19.9B) | (19.4B) | (19.1B) | (17.2B) | (9.2B) |
| Other Non-Op Income/Expense | 32.6B | 6.9B | 4.9B | 26.7B | 8.2B |
| Non-Operating Income (excl Interest) | (22.3B) | (27.5B) | (25.5B) | 16.1B | 13.9B |
| EBT (Pre-Tax Income) | 88.8B | 65.1B | 40.4B | 43.7B | (24.7B) |
| Income Tax Expense | 18.2B | 10.8B | 84.5M | 3.1B | (2.0B) |
| Bottom Line | |||||
| Net Income | 53.7B | 40.4B | 33.6B | 47.0B | 1.1B |
| Earnings from Cont. Ops | 70.7B | 54.3B | 40.3B | 40.6B | (22.7B) |
| Earnings from Discont. Ops | — | — | — | — | 2.5K |
| Bottom Line Net Income | 53.7B | 40.5B | 33.6B | 47.0B | 1.1B |
| Per Share | |||||
| Basic EPS | ₩13,624 | ₩8,493 | ₩7,059 | ₩9,744 | ₩219 |
| Diluted EPS | ₩13,332 | ₩8,423 | ₩7,059 | ₩9,744 | ₩219 |
| Revenue Per Share | ₩201,983 | ₩191,420 | ₩201,166 | ₩182,376 | ₩185,314 |
| Shares | |||||
| Basic Shares Outstanding | 4.8M | 5.0M | 4.8M | 4.8M | 4.9M |
| Diluted Shares Outstanding | 5.0M | 5.0M | 4.8M | 4.8M | 4.9M |
| Profitability Metrics | |||||
| EBITDA | 5.8B | 102.3B | 104.3B | 56.1B | 13.6B |
| D&A | 45.3B | 44.0B | 43.3B | 45.3B | 42.9B |
| EBIT | (39.5B) | 58.3B | 61.0B | 10.8B | (32.9B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026